Clinical Trials
7 trialsNCT06564623 2026-05-08
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Recruiting
NCT03293784 2026-03-30
TICIMEL
Institut Claudius Regaud
Phase 1 Completed
NCT05235438 2023-05-24
Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1 Unknown
NCT02716805 2022-10-12
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
Ludwig Institute for Cancer Research
Phase 1 Terminated
NCT00836407 2020-02-24
Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT01216436 2015-05-25
Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma
Duke University
Phase 1 Terminated
NCT00028431 2014-05-22
Novel Adjuvants for Peptide-Based Melanoma Vaccines
University of Southern California
Phase 1 Completed